Quarterly report [Sections 13 or 15(d)]

Summary of Significant Accounting Policies - Segment Information Significant Expense Categories (Details)

v3.25.1
Summary of Significant Accounting Policies - Segment Information Significant Expense Categories (Details)
 3 Months Ended
Mar. 31, 2025
USD ($)
segment
Mar. 31, 2024
USD ($)
Operating expenses:    
Total research and development $ 2,436,998 $ 343,717
General and administrative expenses 1,992,928 970,384
Total operating expenses 4,429,926 1,314,101
Loss on debt conversion with related party 6,134,120  
Exchange loss, net 23,274  
Net loss before income taxes $ 10,924,952 1,291,335
Number of reportable segments | segment 1  
Single reportable segment    
Operating expenses:    
Clinical $ 1,817,232 2,274
Chemical, manufacturing and controls 135,122 42,637
Research and preclinical 24,134 63,716
Regulatory 21,658 (16)
Other research and development costs 438,852 235,106
Total research and development 2,436,998 343,717
General and administrative expenses 1,992,928 970,384
Total operating expenses 4,429,926 1,314,101
Loss on debt conversion with related party 6,134,120  
Interest expense (income), net 147,090 (22,766)
Exchange loss, net 23,274  
Net loss before income taxes $ 10,734,410 $ 1,291,335